Apogee Therapeutics reports positive Phase 2 APEX trial results for zumilokibart in atopic dermatitis
Apogee announced positive 16-week Part B induction dose optimization results from its Phase 2 APEX trial of zumilokibart, with 65.9% of mid-dose patients achieving EASI-75 endpoints. The company plans to advance the mid-dose into Phase 3 trials in 2H 2026 and secured strategic financing from Blackstone Life Sciences to fund development through commercialization.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day